Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.
Quick Facts
What This Study Found
Oral semaglutide reduced HbA1c by 1.0 percentage point and produced weight loss across all age groups and diabetes durations in real-world practice across seven countries.
Key Numbers
1,615 participants; -1.0% HbA1c at week 38 (95% CI -1.08 to -0.97); 76% on treatment at end of study; 7 countries
How They Did This
Pooled analysis of seven PIONEER REAL prospective, non-interventional, single-arm Phase 4 studies. Outcomes stratified by age, diabetes duration, dose, and baseline characteristics.
Why This Research Matters
Clinical trials use strict criteria. This real-world data shows oral semaglutide works broadly in everyday patients, including older adults and those with long-standing diabetes.
What This Study Doesn't Tell Us
No control group. Single-arm observational design. Pooling across countries introduces heterogeneity. Patients who discontinued were not tracked for outcomes.
Trust & Context
- Original Title:
- Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(1), 73-87 (2025)
- Authors:
- Rudofsky, Gottfried, Amadid, Hanan, Braae, Uffe Christian(2), Catrina, Sergiu-Bogdan, Kick, Anastas, Mandavya, Kabirdev, Roslind, Klaus, Saravanan, Ponnusamy, van Houtum, William, Jain, Akshay B
- Database ID:
- RPEP-13327
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13327APA
Rudofsky, Gottfried; Amadid, Hanan; Braae, Uffe Christian; Catrina, Sergiu-Bogdan; Kick, Anastas; Mandavya, Kabirdev; Roslind, Klaus; Saravanan, Ponnusamy; van Houtum, William; Jain, Akshay B. (2025). Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(1), 73-87. https://doi.org/10.1007/s13300-024-01668-6
MLA
Rudofsky, Gottfried, et al. "Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.." Diabetes therapy : research, 2025. https://doi.org/10.1007/s13300-024-01668-6
RethinkPeptides
RethinkPeptides Research Database. "Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis o..." RPEP-13327. Retrieved from https://rethinkpeptides.com/research/rudofsky-2025-oral-semaglutide-use-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.